{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:03:27Z","timestamp":1780718607104,"version":"3.54.1"},"reference-count":50,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2026,5,31]]},"DOI":"10.5582\/irdr.2026.01043","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:10:09Z","timestamp":1779228609000},"page":"156-165","source":"Crossref","is-referenced-by-count":0,"title":["The skin as a sentinel organ for neurodegeneration: An underrecognized target for dementia prevention"],"prefix":"10.5582","volume":"15","author":[{"given":"Yue","family":"Han","sequence":"first","affiliation":[{"name":"Department of Dermatology, The Union Hospital, Fujian Medical University, Fuzhou, Fujian, China."},{"name":"Division of Global Health &amp; Medicine, Japan Institute for Health Security, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Union Hospital, Fujian Medical University, Fuzhou, Fujian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Union Hospital, Fujian Medical University, Fuzhou, Fujian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Karako","sequence":"additional","affiliation":[{"name":"Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Global Health &amp; Medicine, Japan Institute for Health Security, Tokyo, Japan."},{"name":"National College of Nursing, Japan Institute for Health Security, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","unstructured":"1. World Health Organization. Ageing and health. Geneva: World Health Organization. <i>https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health<\/i> (accessed May 2, 2026)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Cheng Y, Han Y, Wang L, Ma J, Karako K, Shi Y, Song P. Pathways to embed digital health technologies and their governance mechanisms in Long-Term Care Insurance Systems: A comparative review of Japan, South Korea, and China. Biosci Trends. 2026.","DOI":"10.5582\/bst.2026.01098"},{"key":"3","unstructured":"3. World Health Organization. Dementia. Geneva: World Health Organization. <i>https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia<\/i> (accessed May 2, 2026)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Nichols E, Steinmetz JD, Vollset SE, <i>et al<\/i>. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022; 7:e105-e125.","DOI":"10.1002\/alz.051496"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yao D, Gong X, Ma Y, Gong T, Wang G. The prevalence and interventions of xerosis cutis among older adults: A systematic review and meta-analysis. Geriatr Nurs. 2023; 54:219-228.","DOI":"10.1016\/j.gerinurse.2023.09.018"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kottner J, Fastner A, Lintzeri D-A, Blume-Peytavi U, Griffiths CEM, LeBlanc K. Skin health of community-living older people: A scoping review. Arch Dermatol Res. 2024; 316:374.","DOI":"10.1007\/s00403-024-03059-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sefcik JS, McLaurin EJ, Bass EJ, DiMaria-Ghalili RA. Chronic wounds in persons living with dementia: An integrative review. Int J Older People Nurs. 2022; 17:e12447.","DOI":"10.1111\/opn.12447"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Livingston G, Huntley J, Liu KY, <i>et al<\/i>. Dementia prevention, intervention, and care: 2024 report of the Lancet Standing Commission. Lancet. 2024; 404:572-628.","DOI":"10.1016\/S0140-6736(24)01296-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Chowdhary N, Barbui C, Anstey KJ, <i>et al<\/i>. Reducing the risk of cognitive decline and dementia: WHO recommendations. Front Neurol. 2022; 12:765584.","DOI":"10.3389\/fneur.2021.765584"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kim HS, Jung H, Park YH, Heo SH, Kim S, Moon M. Skin-brain axis in Alzheimer&apos;s disease - Pathologic, diagnostic, and therapeutic implications: A hypothetical review. Aging Dis. 2024; 16:901-916.","DOI":"10.14336\/AD.2024.0406"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Zhou Q, Xiong Z, Yang D, Xiong C, Li X. The association between bullous pemphigoid and cognitive outcomes in middle-aged and older adults: A systematic review and meta-analysis. PLoS One. 2023; 18:e0295135.","DOI":"10.1371\/journal.pone.0295135"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Phuan CZY, Yew YW, Tey HL. Bullous pemphigoid and antecedent neurological diseases: An association with dementia. Indian J Dermatol Venereol Leprol. 2017; 83:457-461.","DOI":"10.4103\/0378-6323.198451"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kokkonen N, Herukka SK, Huilaja L, Kokki M, Koivisto AM, Hartikainen P, Remes AM, Tasanen K. Increased levels of the bullous pemphigoid BP180 autoantibody are associated with more severe dementia in Alzheimer&apos;s disease. J Invest Dermatol. 2017; 137:71-76.","DOI":"10.1016\/j.jid.2016.09.010"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tuusa J, Lindgren O, Tertsunen HM, Nishie W, Kokkonen N, Huilaja L, Izumi K, Herukka SK, Miettunen J, Shimizu H, Remes AM, Tasanen K. BP180 autoantibodies target different epitopes in multiple sclerosis or Alzheimer&apos;s disease than in bullous pemphigoid. J Invest Dermatol. 2019; 139:293-299.","DOI":"10.1016\/j.jid.2018.09.010"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Borradori L, Van Beek N, Feliciani C, <i>et al<\/i>. Updated S2K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022; 36:1689-1704.","DOI":"10.1111\/jdv.18220"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lu L, Chen L, Xu Y, Liu A. Global incidence and prevalence of bullous pemphigoid: A systematic review and meta-analysis. J Cosmet Dermatol. 2022; 21:4818-4835.","DOI":"10.1111\/jocd.14797"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Bae S, Yun SC, Kim MC, Yoon W, Lim JS, Lee SO, Choi SH, Kim YS, Woo JH, Kim SY, Kim SH. Association of herpes zoster with dementia and effect of antiviral therapy on dementia: A population-based cohort study. Eur Arch Psychiatry Clin Neurosci. 2021; 271:987-997.","DOI":"10.1007\/s00406-020-01157-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Schmidt SAJ, Veres K, Sorensen HT, Obel N, Henderson VW. Incident herpes zoster and risk of dementia: A population-based Danish cohort study. Neurology. 2022; 99:e660-e668.","DOI":"10.1212\/WNL.0000000000200709"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Taquet M, Dercon Q, Todd JA, Harrison PJ. The recombinant shingles vaccine is associated with lower risk of dementia. Nat Med. 2024; 30:2777-2781.","DOI":"10.1038\/s41591-024-03201-5"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Eyting M, Xie M, Michalik F, <i>et al<\/i>. A natural experiment on the effect of herpes zoster vaccination on dementia. Nature. 2025; 641:438-446.","DOI":"10.1038\/s41586-025-08800-x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Rayens E, Sy LS, Qian L, Ackerson BK, Tubert J, Luo Y, Modha PP, Calderon RO, Chmielewski-Yee E, Oraichi D, Yun H, Koro C, Tseng HF. Recombinant zoster vaccine is associated with a reduced risk of dementia. Nat Commun. 2026; 17:2056.","DOI":"10.1038\/s41467-026-69289-0"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Anderson TC, Masters NB, Guo A, Shepersky L, Leidner AJ, Lee GM, Kotton CN, Dooling KL. Use of recombinant zoster vaccine in immunocompromised adults aged \u2265 19 years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022; 71:80-84.","DOI":"10.15585\/mmwr.mm7103a2"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ma YN, Karako K, Song P, Xia Y. Can the herpes zoster vaccination be a strategy against dementia? Drug Discov Ther. 2025; 19:124-128.","DOI":"10.5582\/ddt.2025.01032"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Zhao J, Li T, Wang J. Association between psoriasis and dementia: A systematic review. Neurologia (Engl Ed). 2024; 39:55-62.","DOI":"10.1016\/j.nrl.2020.12.007"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Charoenngam N, Rittiphairoj T, Ponvilawan B, Ungprasert P. Patients with psoriasis have a higher risk of dementia: A systematic review and meta-analysis. Indian J Dermatol Venereol Leprol. 2021; 87:364-370.","DOI":"10.25259\/IJDVL_732_19"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kim M, Park HE, Lee SH, Han K, Lee JH. Increased risk of Alzheimer&apos;s disease in patients with psoriasis: A nationwide population-based cohort study. Sci Rep. 2020; 10:6454.","DOI":"10.1038\/s41598-020-63550-2"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Gwak YS, Kim SY, Woo CE, Shin K, Son E, Kim JW, Kim SJ, Song TJ, Park HR, Kim K, Ko DS, Kim YH. Association between atopic dermatitis and dementia: Evidence from systematic review, meta-analysis, and Mendelian randomization. Acta Derm Venereol. 2025; 105:adv41321.","DOI":"10.2340\/actadv.v105.41321"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Elmets CA, Leonardi CL, Davis DMR, <i>et al<\/i>. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019; 80:1073-1113.","DOI":"10.1016\/j.jaad.2018.11.058"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Yang J, Zhang S, Wu Q, Chen P, Dai Y, Long J, Wu Y, Lin Y. T cell-mediated skin-brain axis: Bridging the gap between psoriasis and psychiatric comorbidities. J Autoimmun. 2024; 144:103176.","DOI":"10.1016\/j.jaut.2024.103176"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Cameron S, Donnelly A, Broderick C, Arichi T, Bartsch U, Dazzan P, Elberling J, Godfrey E, Gringras P, Heathcote LC, Joseph D, Wood TC, Pariante C, Rubia K, Flohr C. Mind and skin: Exploring the links between inflammation, sleep disturbance and neurocognitive function in patients with atopic dermatitis. Allergy. 2024; 79:26-36.","DOI":"10.1111\/all.15818"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Eichenfield LF, Frazer-Green L, Paller AS, Silverberg JI, Singh AM, Sidbury R. American Academy of Dermatology guidelines: Awareness of comorbidities associated with atopic dermatitis in adults. J Am Acad Dermatol. 2022; 86:1335-1336.e18.","DOI":"10.1016\/j.jaad.2022.01.009"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, Sidbury R. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023; 89:e1-e20.","DOI":"10.1016\/j.jaad.2022.12.029"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, Sidbury R. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024; 90:e43-e56.","DOI":"10.1016\/j.jaad.2023.08.102"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Butler DC, Berger T, Elmariah S, <i>et al<\/i>. Chronic pruritus: A review. JAMA. 2024; 331:2114-2124.","DOI":"10.1001\/jama.2024.4899"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Bollemeijer JF, De Veer MR, Weisshaar E, Brouwer WP, Lahousse L, Gunn DA, Nijsten TEC, Pardo LM. Chronic pruritus in older adults: Prevalence, associations, and pruritus-specific quality of life. Acta Derm Venereol. 2025; 105:adv42396.","DOI":"10.2340\/actadv.v105.44313"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Benn CS, Netea MG, Selin LK, Aaby P. A small jab - A big effect: Nonspecific immunomodulation by vaccines. Trends Immunol. 2013; 34:431-439.","DOI":"10.1016\/j.it.2013.04.004"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Waheed G, Ramadan G, Mohammed HA. Enzymatically-modified isoquercitrin alleviates skin inflammation, mast cell degranulation, and vascular hyperpermeability in a mouse model of plaque psoriasis. Int Immunopharmacol. 2026.","DOI":"10.1016\/j.intimp.2026.116580"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Patients with rosacea have increased risk of dementia. Ann Neurol. 2016; 79:921-928.","DOI":"10.1002\/ana.24645"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Abdi P, Haq Z, Diaz MJ, Maibach HI, Ogunyemi B. Rosacea as a potential risk factor for dementia. Int J Dermatol. 2024; 63:e200-e202.","DOI":"10.1111\/ijd.17335"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Lanza G, Cosentino FII, Ferri R, Lanuzza B, Siragusa M, Tripodi M, Schepis C. Cognitive impairment in inpatients with prurigo nodularis and psychiatric comorbidities. Int J Environ Res Public Health. 2021; 18:6265.","DOI":"10.3390\/ijerph18126265"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Yosipovitch G, Mollanazar N, St\u00e4nder S, <i>et al<\/i>. Dupilumab in patients with prurigo nodularis: Two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023; 29:1180-1190.","DOI":"10.1038\/s41591-023-02320-9"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. St\u00e4nder S, Yosipovitch G, Lacour JP, Legat FJ, Paul C, Reich A, Chaouche K, Ahmad F, Piketty C. Nemolizumab efficacy in prurigo nodularis: Onset of action on itch and sleep disturbances. J Eur Acad Dermatol Venereol. 2022; 36:e943-e946.","DOI":"10.1111\/jdv.18377"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Wilson SR, Th\u00e9 L, Batia LM, <i>et al<\/i>. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell. 2013; 155:285-295.","DOI":"10.1016\/j.cell.2013.08.057"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Wang JP, Kurt-Jones EA, Shin OS, Manchak MD, Levin MJ, Finberg RW. Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages <i>via<\/i> Toll-like receptor 2. J Virol. 2005; 79:12658-12666.","DOI":"10.1128\/JVI.79.20.12658-12666.2005"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Nour AM, Reichelt M, Ku CC, Ho MY, Heineman TC, Arvin AM. Varicella-zoster virus infection triggers formation of an interleukin-1\u03b2 (IL-1\u03b2)-processing inflammasome complex. J Biol Chem. 2011; 286:17921-17933.","DOI":"10.1074\/jbc.M110.210575"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Bubak AN, Beseler C, Como CN, Tyring SK, Haley C, Mescher T, Hassell JE Jr, Cohrs RJ, Potter H, Nagel MA. Acute zoster plasma contains elevated amyloid, correlating with A\u03b242 and amylin levels, and is amyloidogenic. J Neurovirol. 2020; 26:422-428.","DOI":"10.1007\/s13365-020-00830-7"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Bubak AN, Como CN, Coughlan CM, Johnson NR, Hassell JE, Mescher T, Niemeyer CS, Mahalingam R, Cohrs RJ, Boyd TD, Potter H, Russ HA, Nagel MA. Varicella-zoster virus infection of primary human spinal astrocytes produces intracellular amylin, amyloid-\u03b2, and an amyloidogenic extracellular environment. J Infect Dis. 2020; 221:1088-1097.","DOI":"10.1093\/infdis\/jiz560"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, Chalmers JR, Childs M, Walton S, Harman K, Chapman A, Whitham D, Nunn AJ; UK Dermatology Clinical Trials Network BLISTER Study Group. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: A pragmatic, non-inferiority, randomised controlled trial. Lancet. 2017; 389:1630-1638.","DOI":"10.1016\/S0140-6736(17)30560-3"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Beck LA, Silverberg JI, Simpson EL, Yosipovitch G, Eckert L, Guillemin I, Chen Z, Ardeleanu M, Plaum S, Graham N, Ruddy M, Pirozzi G, Gadkari A. Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: Results from five randomized clinical trials. J Eur Acad Dermatol Venereol. 2021; 35:e130-e133.","DOI":"10.1111\/jdv.16865"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Gelfand JM, Shin DB, Duffin KC, <i>et al<\/i>. A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S). J Invest Dermatol. 2020; 140:1784-1793.e2.","DOI":"10.1016\/j.jid.2020.01.025"}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/15\/2\/15_2026.01043\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:48:58Z","timestamp":1780717738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/15\/2\/15_2026.01043\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2026.01043","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,31]]},"article-number":"2026.01043"}}